



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 16TH MAY 2018 AT
12.30pm

IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr T MacKenzie (TM)	GP, EL CCG

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
Ms N Everitt	Clinical Procurement Specialist Nurse

2018/078: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr Y Naheed (YN)	GP, EL CCG

2018/079: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/080: MINUTES OF APRIL MEETING:

Accepted as a correct record.

2018/081: MATTERS ARISING:

2018/040: Homely Remedies Policy – updated in line with comments from various groups. Infection control raised a concern over use of loperamide in elderly and risk of c.difficile. ELMMB agreed to remove diarrhoea section. Products included to be aligned with formulary (ie dry skin products). Approved for use once amended.

2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines – in progress.

2018/073: Rifaxamin – Guidelines for Prescribing – gastroenterology advised it could be continued beyond 6 months if suitable, and refer patients back to specialist who require review. The intention is to prescribe with lactulose. Document to be updated as a prescribing guidance and brought back for review.

ACTION: Update document for next meeting.

2018/082: CONTINENCE & CATHETER CARE FORMULARY

Nicola Everett, Clinical Procurement Specialist Nurse, in attendance for this item. The formulary has been updated by the North West Procurement Forum and this has been supported by CCGs to align products across the services. It has been shared and supported by urology nurses. Specialist items are shown as amber and red for restricted prescribing according to specialist knowledge and skills. It was suggested to remove prices from on-line version to avoid the need for monthly review. ELMMB supported the proposal to include on the Microguide Application to enable ready access by District Nurses and other community clinicians. Approved when front sheet with logo, review date and ownership are added.

Resolved: Continence & Catheter Care Formulary approved.

2018/083: NEW (UNLICENSED) PRODUCT REQUEST – BRIVARACETAM IN CHILDREN

Brivaracetam which is currently unlicensed in children is requested for use in children under 16 for seizures when other anticonvulsants have been tried with limited success. Use would be recommended by a tertiary centre to improve quality of life and reduce hospital interventions. Approved for use in children by paediatric specialists.

Resolved: Brivaracetam in children approved for specialist paediatric use.

Traffic Light: RED

2018/084: LMMG CONSULTATIONS (for June LMMG)

Rivaroxaban extended use review – supported.

Imiquimod & Fluorouracil cream Recommendation - dermatologists consider suitable for GPs to prescribe and would like to see given green traffic light but GPs would want specialists (dermatologist, GPwSI) to initiate treatment, amber traffic light.

Psoriasis Biologics Pathway – update - supported.

Resolved: Comments to be sent to LMMG

2018/085: LMMG RECOMMENDATIONS (from Apr LMMG)

Guidelines for the Management of Behavioural & Psychological Symptoms of dementia (BPSD) in Primary and Secondary Care – accepted as written for use in ELHE.

Guideline for Antihyperglycaemic Therapy in adults with Type 2 Diabetes – updated - accepted as written for use in ELHE. Comments on local use of GLP-1 with insulin to be discussed with diabetologists.

Denosumab Shared Care Guideline – updated - accepted as written for use in ELHE.

DMARDs Shared Care Agreement Form – agreed form should be used in ELHE and implementation discussed. VG to set up task & finish group to look at implementation in the trust to ensure the forms are used.

Action: VG to set up Task and Finish Group for implementation.

2018/086: FORMULARY UPDATES

Ciprofloxacin ear drops – (unlicensed) to remain on formulary in addition to Cilodex® ear drops.
Traffic light: Red

Hydrocortisone sodium succinate injection – changed from red to Amber traffic light to allow for prescribing in primary care for emergency management of adrenal insufficiency.
Traffic light: Amber

Medroxyprogesterone acetate - Sayana Press injection to be included on formulary in addition to Depo-Provera.

Resolved: Formulary to be updated as above

2018/087: TEMPERATURE CONTROL LEAFLET

Leaflet for use in primary care adapted from ELHT leaflet.

Resolved: Temperature Control Leaflet accepted.

2018/088: OTC GUIDANCE FOR CCG's

This is a national document that supports and compliments local policies. Guidance acknowledged.

Self-care items to be flagged on the online formulary. Ideally these should not be recommended for GP's to prescribe.

Action: JV/LP to flag self-care items on online formulary.

EXTRA ITEM: RMOC BRIEFING – BEST VALUE BIOLOGICS: ADALIMUMAB

Biosimilar adalimumab will be available from October 2018. RMOC have issued this briefing for CCG's and trusts to be prepared to implement changes to use the best value biologic. The trust should liaise with clinicians and patients, and have a plan for procurement and homecare arrangements to implement. The trust homecare team have started the planning. ELMMB to be regularly updated with progress.

Resolved: Trust to plan for implementation of best value biologic of adalimumab.

2018/089: NICE RECOMMENDATIONS (from Apr)

Avelumab for treating metastatic Merkel cell carcinoma [TAG 517] is recommended as an option by NICE. Approved in line with NICE.

NHSE Cancer Drugs Fund

Traffic Light: RED

Tocilizumab for treating giant cell arteritis [TAG 518] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TAG 519) is recommended as an option by NICE. Approved in line with NICE.

NHSE Cancer Drugs Fund

Traffic Light: RED

STANDING ITEMS

2018/090: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Apr 2018

Minutes acknowledged

2018/091: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – Mar 2018

Minutes acknowledged

2018/092: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Apr 2018

Minutes acknowledged

2018/093: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE ANNUAL REPORT – 2017- 2018

Report acknowledged

DATE OF NEXT MEETING – Wednesday 20TH June 2018 12.30pm, Seminar Room 2, Learning & Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 16TH MAY 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2018/052	LMMG Recommendations (from Feb LMMG) Melatonin guidelines – ELHT guideline to include beneficial response information from LCFT guidance.	Dr Perera	May 18
2018/073	Rifaxamin – Guidelines for Prescribing – to be discussed with gastroenterology directorate. Update document	LR	Jun 18
2018/085	LMMG Recommendations (from Apr LMMG) - DMARDs Shared Care Agreement Form – task & finish group to look at implementation to be set up	VG	Sept 18
2018/088	OTC GUIDANCE FOR CCG's – Self-care items to be flagged on online formulary	JV/LP	Jun 18